For the last three years, the world has obsessed over generative AI that can write and create. By the end of 2026, we'll see ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

Founded in 2014, Insilico finally pushed an IPO over the line last month, completing a much-oversubscribed listing on the ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...

The Danish drugmaker said the drug will be available from today at prices starting from $149 per month for cash purchasers.